DYN Stock Price | Dyne Therapeutics Inc P/E, Revenue, EPS, & Forecasts

Dyne Therapeutics Inc • DYN

DYN current price

$23.97+75.73%

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs
News

-2.48%

-19.02%

-30.76%

-32.33%

+75.73%

MAX

+0.29%

About Dyne Therapeutics Inc

Ticker

DYN

Trading on

NASDAQ

ISIN

US26818M1080

Industry

Biotechnology

Sector

Healthcare

CEO

John G. Cox M.B.A.

Headquarters

1560 Trapelo Road, Waltham, MA, United States, 02451

Employees

173

Website

dyne-tx.com

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Metrics

BasicAdvanced

Market cap

$2.44B

P/E ratio

EPS

-$3.58

Dividend Yield

0.00%

Beta

1.1

Forward P/E ratio

EBIDTA

$-313M

Ex dividend date

Price & volume

Market cap

$2.44B

Average daily volume

0.8M

90-day return

-30.76%

30-day return

-19.02%

7-day return

-2.48%

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

0.19

Trailing P/E

Price to sales

Price to book

3.45

Earnings

EPS

-$3.58

EPS estimate (current quarter)

-$0.71

EPS estimate (next quarter)

-$0.74

EBITDA

$-313M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

1.1

52-week High

$47.45

52-week Low

$12.33

50-day moving average

$29.48

200-day moving average

$32.68

Short ratio

9.33

Short %

12.08%

Management effectiveness

ROE (TTM)

68.68%

ROA (TTM)

40.35%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

102M

Float

74.8M

Insiders %

0.77%

Institutions %

112.41%

Analyst Insights & forecasts

92% Buy

8% Hold

0% Sell

Based on information from 12 analysts.

Average price target

$50.42

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$1.09

-$0.92

18.48%

Q4 • 23Beat

-$0.81

-$0.80

1.25%

Q1 • 24Beat

-$0.70

-$0.72

2.78%

Q2 • 24Beat

-$0.96

-$0.71

35.61%

Q3 • 24Beat

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-65.1M

∞%

Q2 • 24

$0M

$-97.1M

∞%

Q3 • 24

NaN%

49.19%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$826M

$50.7M

6.14%

Q2 • 24

$769M

$63.3M

8.23%

Q3 • 24

6.91%

24.88%

34.15%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-54.9M

$11.2M

$380M

$-55.7M

Q2 • 24

$-74.6M

$-19.4M

$18M

$-74.9M

Q3 • 24

36.02%

273.64%

95.26%

34.38%

QoQ growth

QuarterlyAnnual

Sentiment analysis

-1.5

Extreme greed

+1.5

1.50

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Dyne Therapeutics Inc share?

Dyne Therapeutics Inc shares are currently traded for $23.97 per share.

How many shares does Dyne Therapeutics Inc have?

Dyne Therapeutics Inc currently has 102M shares.

Does Dyne Therapeutics Inc pay dividends?

No, Dyne Therapeutics Inc doesn't pay dividends.

What is Dyne Therapeutics Inc 52 week high?

Dyne Therapeutics Inc 52 week high is $47.45.

What is Dyne Therapeutics Inc 52 week low?

Dyne Therapeutics Inc 52 week low is $12.33.

What is the 200-day moving average of Dyne Therapeutics Inc?

Dyne Therapeutics Inc 200-day moving average is $32.68.

Who is Dyne Therapeutics Inc CEO?

The CEO of Dyne Therapeutics Inc is John G. Cox M.B.A..

How many employees Dyne Therapeutics Inc has?

Dyne Therapeutics Inc has 173 employees.

What is the market cap of Dyne Therapeutics Inc?

The market cap of Dyne Therapeutics Inc is $2.44B.

What is the P/E of Dyne Therapeutics Inc?

The current P/E of Dyne Therapeutics Inc is null.

What is the EPS of Dyne Therapeutics Inc?

The EPS of Dyne Therapeutics Inc is -$3.58.

What is the PEG Ratio of Dyne Therapeutics Inc?

The PEG Ration of Dyne Therapeutics Inc is 0.19.

What do analysts say about Dyne Therapeutics Inc?

According to the analysts Dyne Therapeutics Inc is considered a buy.

Dyne Therapeutics Inc news

thumb_up_alt

•Positive

FDA's new accelerated approval guidance to benefit rare disease drug development, analysts believe

New Food and Drug Administration (FDA) guidance on accelerated approval for drugs targeting “serious conditions” appears to be a positive move for rare diseases, analysts at Jefferies believe. The FDA earlier this month published the draft guidance on its policies and procedures for the accelerated approval (AA) pathway for drugs for serious conditions that fulfil an unmet medical need.

Proactive Investors•13 Dec 2024, 16:20

thumb_up_alt

•Positive

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

Dyne Therapeutics, Inc. develops treatments for muscle diseases using its FORCE platform, with promising candidates DYNE-101 and DYNE-251 targeting DM1 and DMD, respectively. DYNE-251 shows significant improvement over Sarepta's Eteplirsen in Phase 1/2 trials, potentially accelerating approval and boosting DYN's stock. Key risks include executive reshuffling and potential hidden issues with IP, but current data and market potential make DYN attractive for speculative investors.

Seeking Alpha•11 Nov 2024, 23:15

thumbs_up_down

•Neutral

Dyne Therapeutics to Present at Upcoming Investor Conferences

WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following upcoming investor conferences:

GlobeNewsWire•07 Nov 2024, 21:15